Table 2.

Results of a univariate analysis of the overall survival according to the clinicopathological factors

Characteristics		n	HR	95 % CI	p value*
Sex	Male	13	0.64	0.19–2.24	0.459
	Female	7	1
Age (years)	> 70	13	0.20	0.05–0.67	0.004
	< 70	7	1
Histological type	Well/mod	14	2.10	0.54–13.77	0.331
	Poor/muc	6	1
Size of primary tumor (cm)	≥ 5	10	4.10	1.02–20.4	0.041
	< 5	10	1
Type of gastrectomy (partial; distal 11, proximal 1)	Total gastrectomy	8	5.60	1.40–27.82	0.009
	Partial gastrectomy	12	1
Serosal invasion	Present	4	1.17	0.17–4.89	0.841
	Absent	16	1
Lymph node metastasis	N2/N3	12	1.68	0.50–6.53	0.406
	N0/N1	8	1
Lymphatic invasion	ly2/ly3	11	0.39	0.08–1.35	0.150
	ly0/ly1	9	1
Venous invasion	v2/v3	11	0.57	0.16–1.92	0.354
	v0 /v1	9	1
Number of hepatic tumors	Solitary	11	0.34	0.08–116	0.077
	Multiple	9	1
Maximum size of the metastatic tumor	≤ 3 cm	14	0.41	0.12–1.40	0.197
	> 3 cm	6	1
Time of hepatectomy	Synchronous	11	1.31	0.39–4.59	0.660
	Metachronous‡	9	1
Repeat hepatectomy	Repeat	5	0.81	0.17–2.87	0.758
	Once	15	1
Postoperative chemotherapy (cycle)	≥ 3	11	0.47	0.13–1.57	0.203
	< 3	9	1
CEA (ng/mL)	≥ 6.0	6	5.57	1.34–27.79	0.091
	< 6.0	14	1
CA19-9 (U/mL)	≥ 37.0	4	7.94	1.42–44.33	0.003
	< 37.0	16	1
AFP	Positive	4	1.66	0.36–5.78	0.453
	Negative	16	1

HR hazard ratio, CI confidence interval, Inf infinity, Well well-differentiated tubular adenocarcinoma, Mod moderately differentiated tubular adenocarcinoma, Poor poorly differentiated adenocarcinoma, Muc mucinous adenocarcinoma, CEA carcinoembryonic antigen, CA19-9 carbohydrate antigen 19-9, AFP alpha-fetoprotein

*Log-rank test

^‡The median interval between gastrectomy and primary hepatectomy was 18.0 months (range 4–42)